Therapeutics Market – Market Outlook & Trends
The Global PneumoniaTherapeutics Market valued at USD 1.7 billion in 2019, is expected to reach USD
2.84 billion by 2026, at a CAGR of 7.60% during the projection period. The worldwide pneumonia therapeutics market
is growing due to rising air pollution and increasing the geriatric population
across the world. Numerous environmental wastes like chemicals spread harmful
microorganisms such as fungi, viruses, and bacteria, which cause pneumonia.
Most of the pharmaceutical companies undertake substantial research activities
for the development of novel drugs, enhancing market growth. Besides, rapid
urbanization and industrialization, advanced levels of air pollution, unhealthy
routine, and growing smoking populace have increased the cases of asthma and
pneumonia in urban areas. It leads to the increasing demand for pneumonia
therapeutics, thereby fueling the growth of the Global Pneumonia Therapeutics
Market. However, the lack of consciousness among the citizens about its drug
& cure and traditional treatment for pneumonia may restrain the development
of the pneumonia therapeutics market in the prospect.
Global Pneumonia Therapeutics
Market – Overview
Pneumonia is a seditious
disorder disturbing the air sacs or alveoli in the lungs, and it may lead to
fever, dry cough, chest pain, breathing trouble, etc. It is usually caused by
germs and bacteria and mostly afflicts the person suffering from cold and flu.
It can be life-threatening for young children, infants, and older adults. It
can be detected with the help of blood tests, X-rays, physical examinations,
etc. Vaccination helps avoid pneumonia, whereas patients with critical situations,
patients need to be hospitalized and help with oxygen therapy. Generally,
antibiotics like quinolones, macrolides, etc. are used for treating pneumonia.
Surging Cases of
Pneumonia across the Globe
The unhealthy lifestyle
and polluted atmosphere enhance the prevalence of pneumonia across different
age-groups of population. Besides, Geriatric or senior citizens are vulnerable
to pneumonia due to weak immune systems. Heart disease, diabetes, and other
serious diseases are very communal in ageing persons, which eventually raises
the risk of pneumonia. The geriatric section accounted for around 20% market
share in 2019 and is projected to rise over the forecast period. Also, the
geriatric population base is prone to get affected by flu and other
lung-related disorders that sometimes grow into pneumonia.
initiatives in the Asia Pacific Region
Asia Pacific pneumonia
therapeutics market held a substantial revenue share of 34% in 2019 due to
growing cases of pneumonia. Governments of various nations are committed to
reducing the prevalence of pneumonia with substantial investment outlay and
remedial measures, which is anticipated to enhance the market growth for the
Increasing R&D Outlay
for New Product Development
The private and state
players are allocating more and more outlay for R & D, emphasizing
effective therapeutics. Currently, the market is witnessing a significant
number of new product launches, driving the market growth. The major companies
in pneumonia therapeutics market such as Sanofi, Eli Lilly, AstraZeneca, Merck
& Co. Novartis, GlaxoSmithKline, Pfizer, and Baxter International Inc.
invest substantially in research applications for developing novel drugs and
Impact of COVID-19 in
main causes of COVID-19 are cough and sneeze, and people at large want to
mitigate these symptoms or causes at the earliest. They tend to consume the
remedial drugs to get cured, which again enhances the market for cough or flu
subsiding drugs. In the wake of coronavirus, the pharmaceutical industry has
received a major boost, assuring the substantial market growth during the
Therapeutics Market: Segmentation
Global Pneumonia Therapeutics
Market is segmented on Drug Class (Antibacterial, Antiviral, Antifungal), Age
Group (Pediatric, Adult, Geriatric), Infection Type (Hospital-acquired
Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated
Pneumonia [VAP]), Distribution Channel (Hospital Pharmacies, Retail Pharmacies,
In Drug Class, the
Antiviral drugs market segment is anticipated to witness approximately 7.5%
CAGR during the forecast period, due to increasing viral pneumonia which spreads
from the fluid present in the air dews after distinct coughs or sneezes. Various
remedial options, including Oseltamivir and Acyclovir, are available to give
the antiviral contamination and diminish the severity of flu viruses into the
body. These options are expected to induce market growth.
Based on the infection
type, the HAP market accounted for more than USD 352 Million in 2019 and is
expected to grow with the rising hospital stays during the forthcoming period.
Hospital-acquired pneumonia is a lung contamination that occurs during hospital
stays, which leads to serious issues such as renal failure, respiratory
failure, and empyema. Increasing incidences of hospital-acquired pneumonia will
induce the request for pneumonia therapeutics drugs.
Based on Distribution
Channel, the online pharmacies market will display around 8% CAGR throughout
the prediction timeframe. Online pharmacies are better than offline stores in
terms of low product and transaction costs. Moreover, online pharmacies offer
suitability and convenience to persons with restricted mobility. Furthermore,
these pharmacies provide doorstep distribution within a short period that
surges their fondness. The factors mentioned above are likely to drive growth
in the online segment during the projection timeframe.
Based on region, Global
Pneumonia Therapeutics Market is segmented by key regions— North America,
Europe, Asia Pacific, South America, and the Middle East & Africa.
Therapeutics Market: Regional Insights
The markets in North
America and Europe hold vital market share because of well-developed healthcare
sector, increasing occurrences of community-acquired pneumonia, and presence of
well-known players operating in the target market through various countries in
this region. The market in the Asia Pacific is anticipated to see the fastest
growth, owing to growing government spending on healthcare and the presence of
leading players in the developing economies such as India and China in this
The leading players
considered for market analysis are Abbott Laboratories, Allergan, AstraZeneca,
Bayer, Cipla, GlaxoSmithKline, Lupin Pharmaceuticals, Merck, Mylan, Novartis,
Pfizer, Sanofi and other prominent players.
Ø In September 2018, Pfizer received breakthrough therapy
designation from the U.S. FDA for its 20-Valent Pneumococcal Conjugate Vaccine.
This vaccine is useful for the prevention of pneumonia and invasive diseases. The
development has enhanced the market position and portfolio of the company.
Ø In June 2019, Merck received FDA approval for Zerbaxa drug, used
in the treatment of ventilator-associated pneumonia and hospital-acquired
bacterial pneumonia. It has widened the firm’s pneumonia therapeutics portfolio.
Scope of the Report
Historical data – 2016-2018
Base Year – 2019
Forecast – 2020 – 2026
Revenue in USD Billion
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South Korea, China, India, South Korea UAE, South Africa, Saudi Arabia.
By Drug Class, By Age Group, By Infection Type, By Distribution Channel, By Region
Abbott Laboratories, Allergan, AstraZeneca, Bayer, Cipla, GlaxoSmithKline, Lupin Pharmaceuticals, Merck, Mylan, Novartis, Pfizer, Sanofi and other prominent players.
By Drug Class
Ø Antibacterial Drugs
Ø Antiviral Drugs
Ø Antifungal Drugs
By Age Group
By Infection Type
Ø Hospital-acquired Pneumonia [HAP]
Ø Community-acquired Pneumonia [CAP]
Ø Ventilator-associated Pneumonia [VAP]
By Distribution Channel
Ø Hospital Pharmacies
Ø Retail Pharmacies
Ø Online Pharmacies
Ø North America
Ø Asia Pacific
Ø South America
Ø Middle East & Africa
The objective of the Study:
Ø To analyze and estimate the Global Pneumonia Therapeutics Market size, in terms of value.
Ø To examine the market segmentation carefully and estimate the
market size, in terms of value, based on the region by segmenting the Global Pneumonia Therapeutics Market into
five regions, namely, North America, Europe, Asia Pacific, Rest of the World
and their leading countries.
Ø To outline, categorize and project the Global Pneumonia Therapeutics Market based on
the Drug Class, Age Group, Infection Type, Distribution Channel and Region.
Ø To examine competitive developments in drugs, diagnostics, and distribution
channels within the Global Pneumonia
Ø To highlight market dynamics such as drivers, restraints,
opportunities, and challenges and their impact.
Ø To provide a detailed competitive landscape, including major
players, their strategic profiles, and market shares.
Business Questions Answered by the Report
Ø How will the market drivers, restraints, and opportunities
affect the market dynamics?
Ø What will be the market size in terms of value and volume and
market statistics with a detailed classification?
Ø Which segment dominates the market or region, and which one will
be the fastest-growing, and why?
Ø Who are the key players in the market, and what is their share?
Ø What is the strategy adopted by key players, and how does it
affect the existing and new players?
Customization Scope for the Client
Client satisfaction is our first and last priority, and that is
why BlueWeave Consulting offers customization as per client’s specific needs.
The following customization options are available for the report:
Ø Additional Company Information
Ø Detail Analysis of five additional companies
Ø Additional country analysis
Ø Detailed segment analysis
Recent healthcare Reports: Global | Regional || Medical Devices